फिनकैश »म्यूचुअल फंड इंडिया »कोरोनावायरस के बीच चमक रहा फार्मा सेक्टर
Table of Contents
कोरोनावाइरस वैश्विक को प्रभावित किया हैअर्थव्यवस्था, जिसके कारण घरेलू इक्विटी में भारी गिरावट का सामना करना पड़ा। ज्यादातर शेयरों ने निचले रिकॉर्ड को छुआ है। मार्च के दूसरे सप्ताह के बाद से बीएसई सेंसेक्स और एनएसई निफ्टी का सबसे खराब प्रदर्शन रहा। 18 मार्च को सेंसेक्स 1709 अंक गिरकर 28,896 अंक पर बंद हुआ जबकि निफ्टी 8500 अंक से नीचे चला गया।
तबाही के बीच, फार्मा क्षेत्र कम प्रभावित दिखता है क्योंकि यह अच्छा मुनाफा कमा रहा है। मौजूदा उथल-पुथल में सुरक्षित पनाहगाह की तलाश करने वाले निवेशक विचार कर सकते हैंनिवेश फार्मा क्षेत्र में यह सुधार की प्रवृत्ति दिखा रहा है क्योंकिआय.
हाल के वर्षों में, फार्मास्युटिकल क्षेत्र में वृद्धि हुई है क्योंकि अस्पतालों की नई सूची और डायग्नोस्टिक कंपनियों को टोकरी में और जोड़ा गया है। सरकार की नीतियां और उत्थानआय स्तर इस क्षेत्र में मजबूत वृद्धि दे रहे हैं।
2017 में फार्मास्युटिकल क्षेत्र का मूल्य 33 बिलियन अमेरिकी डॉलर था। 2018 में, भारतीय फार्मास्युटिकल निर्यात 17.27 बिलियन अमेरिकी डॉलर था और 2019 में 19.14 बिलियन अमेरिकी डॉलर तक पहुंच गया। फार्मास्युटिकल उद्योग का विस्तार होने का अनुमान है।सीएजीआर 2020 तक 22.4%।
भारतीय कंपनियों को 2017 में अमेरिकी खाद्य एवं औषधि प्रशासन से 304 संक्षिप्त न्यू ड्रग एप्लिकेशन प्राप्त हुए। फार्मा क्षेत्र का विस्तार होगा और 2025 तक यह 55 बिलियन अमेरिकी डॉलर तक पहुंच जाएगा।
फार्मास्यूटिकल्स थोक दवाओं, मध्यवर्ती, दवा निर्माण, जैविक, हर्बल उत्पादों आदि का निर्यात करता है। जैव-कृषि, जैव-उद्योग, जैव-फार्मास्युटिकल्स आदि से समझौता करने वाले भारत के जैव प्रौद्योगिकी उद्योग के सालाना लगभग 30% की मध्यम दर से बढ़ने की उम्मीद है और आने वाले वर्षों में इसके 100 बिलियन अमेरिकी डॉलर तक पहुंचने की उम्मीद है।
फार्मा क्षेत्र निम्नलिखित कारकों के कारण निवेश और व्यापार के लिए कई अवसर प्रदान करता है:
(Erstwhile SBI Pharma Fund) To provide the investors maximum growth opportunity through equity
investments in stocks of growth oriented sectors of the economy. SBI Healthcare Opportunities Fund is a Equity - Sectoral fund was launched on 31 Dec 04. It is a fund with High risk and has given a Below is the key information for SBI Healthcare Opportunities Fund Returns up to 1 year are on The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies. Nippon India Pharma Fund is a Equity - Sectoral fund was launched on 5 Jun 04. It is a fund with High risk and has given a Below is the key information for Nippon India Pharma Fund Returns up to 1 year are on (Erstwhile UTI Pharma & Healthcare Fund) The Investment objective of the Scheme is capital appreciation through investments in equities and equity related instruments of the Pharma & Healthcare sectors. UTI Healthcare Fund is a Equity - Sectoral fund was launched on 28 Jun 99. It is a fund with High risk and has given a Below is the key information for UTI Healthcare Fund Returns up to 1 year are on Fund NAV Net Assets (Cr) 3 MO (%) 6 MO (%) 1 YR (%) 3 YR (%) 5 YR (%) 2024 (%) SBI Healthcare Opportunities Fund Growth ₹420.859
↑ 2.85 ₹3,671 6.5 2.1 21.1 27.5 25.4 42.2 Nippon India Pharma Fund Growth ₹495.418
↓ -4.50 ₹8,260 5.2 -0.8 14.1 22 22.2 34 UTI Healthcare Fund Growth ₹271.409
↓ -2.30 ₹1,037 4.2 -2.5 20.5 22.6 21.9 42.9 Note: Returns up to 1 year are on absolute basis & more than 1 year are on CAGR basis. as on 19 May 25 1. SBI Healthcare Opportunities Fund
CAGR/Annualized
return of 15.6% since its launch. Ranked 34 in Sectoral
category. Return for 2024 was 42.2% , 2023 was 38.2% and 2022 was -6% . SBI Healthcare Opportunities Fund
Growth Launch Date 31 Dec 04 NAV (19 May 25) ₹420.859 ↑ 2.85 (0.68 %) Net Assets (Cr) ₹3,671 on 30 Apr 25 Category Equity - Sectoral AMC SBI Funds Management Private Limited Rating ☆☆ Risk High Expense Ratio 2.09 Sharpe Ratio 0.84 Information Ratio 0.73 Alpha Ratio 2.95 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-15 Days (0.5%),15 Days and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Apr 20 ₹10,000 30 Apr 21 ₹15,282 30 Apr 22 ₹15,865 30 Apr 23 ₹16,168 30 Apr 24 ₹24,854 30 Apr 25 ₹30,132 Returns for SBI Healthcare Opportunities Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 19 May 25 Duration Returns 1 Month 1.8% 3 Month 6.5% 6 Month 2.1% 1 Year 21.1% 3 Year 27.5% 5 Year 25.4% 10 Year 15 Year Since launch 15.6% Historical performance (Yearly) on absolute basis
Year Returns 2024 42.2% 2023 38.2% 2022 -6% 2021 20.1% 2020 65.8% 2019 -0.5% 2018 -9.9% 2017 2.1% 2016 -14% 2015 27.1% Fund Manager information for SBI Healthcare Opportunities Fund
Name Since Tenure Tanmaya Desai 1 Jun 11 13.92 Yr. Data below for SBI Healthcare Opportunities Fund as on 30 Apr 25
Equity Sector Allocation
Sector Value Health Care 91.24% Basic Materials 6.15% Asset Allocation
Asset Class Value Cash 2.6% Equity 97.4% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Dec 17 | SUNPHARMA14% ₹513 Cr 2,800,000 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB7% ₹243 Cr 400,000
↑ 25,000 Max Healthcare Institute Ltd Ordinary Shares (Healthcare)
Equity, Since 31 Mar 21 | MAXHEALTH6% ₹231 Cr 2,100,000
↓ -100,000 Cipla Ltd (Healthcare)
Equity, Since 31 Aug 16 | 5000875% ₹186 Cr 1,200,000 Lonza Group Ltd ADR (Healthcare)
Equity, Since 31 Jan 24 | LO3A5% ₹182 Cr 300,000 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 23 | 5002575% ₹176 Cr 840,000 Poly Medicure Ltd (Healthcare)
Equity, Since 31 Aug 24 | POLYMED4% ₹139 Cr 540,000 Mankind Pharma Ltd (Healthcare)
Equity, Since 30 Apr 23 | MANKIND4% ₹138 Cr 560,000 Krishna Institute of Medical Sciences Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5433084% ₹134 Cr 2,034,372
↓ -65,628 Jupiter Life Line Hospitals Ltd (Healthcare)
Equity, Since 31 Aug 23 | JLHL3% ₹117 Cr 800,000 2. Nippon India Pharma Fund
CAGR/Annualized
return of 20.5% since its launch. Ranked 35 in Sectoral
category. Return for 2024 was 34% , 2023 was 39.2% and 2022 was -9.9% . Nippon India Pharma Fund
Growth Launch Date 5 Jun 04 NAV (20 May 25) ₹495.418 ↓ -4.50 (-0.90 %) Net Assets (Cr) ₹8,260 on 30 Apr 25 Category Equity - Sectoral AMC Nippon Life Asset Management Ltd. Rating ☆☆ Risk High Expense Ratio 1.88 Sharpe Ratio 0.54 Information Ratio -0.22 Alpha Ratio -1.9 Min Investment 5,000 Min SIP Investment 100 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Apr 20 ₹10,000 30 Apr 21 ₹15,389 30 Apr 22 ₹15,981 30 Apr 23 ₹15,783 30 Apr 24 ₹23,851 30 Apr 25 ₹27,660 Returns for Nippon India Pharma Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 19 May 25 Duration Returns 1 Month 1.7% 3 Month 5.2% 6 Month -0.8% 1 Year 14.1% 3 Year 22% 5 Year 22.2% 10 Year 15 Year Since launch 20.5% Historical performance (Yearly) on absolute basis
Year Returns 2024 34% 2023 39.2% 2022 -9.9% 2021 23.9% 2020 66.4% 2019 1.7% 2018 3.6% 2017 7.6% 2016 -10.6% 2015 19.4% Fund Manager information for Nippon India Pharma Fund
Name Since Tenure Sailesh Raj Bhan 1 Apr 05 20.09 Yr. Kinjal Desai 25 May 18 6.94 Yr. Data below for Nippon India Pharma Fund as on 30 Apr 25
Equity Sector Allocation
Sector Value Health Care 99.71% Asset Allocation
Asset Class Value Cash 0.29% Equity 99.71% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA14% ₹1,146 Cr 6,256,349 Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB10% ₹791 Cr 1,298,808 Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 5002576% ₹521 Cr 2,483,991
↓ -414,135 Cipla Ltd (Healthcare)
Equity, Since 31 May 08 | 5000876% ₹496 Cr 3,200,000 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Sep 20 | APOLLOHOSP5% ₹453 Cr 648,795 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY5% ₹434 Cr 3,662,170 GlaxoSmithKline Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Aug 22 | GLAXO4% ₹300 Cr 1,011,921 Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 5434274% ₹292 Cr 3,627,277 Vijaya Diagnostic Centre Ltd (Healthcare)
Equity, Since 30 Sep 21 | 5433503% ₹283 Cr 2,831,564 Abbott India Ltd (Healthcare)
Equity, Since 31 May 11 | ABBOTINDIA3% ₹267 Cr 88,883
↓ -2,050 3. UTI Healthcare Fund
CAGR/Annualized
return of 14.8% since its launch. Ranked 40 in Sectoral
category. Return for 2024 was 42.9% , 2023 was 38.2% and 2022 was -12.3% . UTI Healthcare Fund
Growth Launch Date 28 Jun 99 NAV (20 May 25) ₹271.409 ↓ -2.30 (-0.84 %) Net Assets (Cr) ₹1,037 on 30 Apr 25 Category Equity - Sectoral AMC UTI Asset Management Company Ltd Rating ☆ Risk High Expense Ratio 2.38 Sharpe Ratio 0.69 Information Ratio -0.24 Alpha Ratio 0.57 Min Investment 5,000 Min SIP Investment 500 Exit Load 0-1 Years (1%),1 Years and above(NIL) Growth of 10,000 investment over the years.
Date Value 30 Apr 20 ₹10,000 30 Apr 21 ₹15,214 30 Apr 22 ₹15,571 30 Apr 23 ₹15,015 30 Apr 24 ₹22,423 30 Apr 25 ₹27,036 Returns for UTI Healthcare Fund
absolute basis
& more than 1 year are on CAGR (Compound Annual Growth Rate)
basis. as on 19 May 25 Duration Returns 1 Month 1.3% 3 Month 4.2% 6 Month -2.5% 1 Year 20.5% 3 Year 22.6% 5 Year 21.9% 10 Year 15 Year Since launch 14.8% Historical performance (Yearly) on absolute basis
Year Returns 2024 42.9% 2023 38.2% 2022 -12.3% 2021 19.1% 2020 67.4% 2019 1.2% 2018 -7.5% 2017 6.2% 2016 -9.7% 2015 12.4% Fund Manager information for UTI Healthcare Fund
Name Since Tenure Kamal Gada 2 May 22 3 Yr. Data below for UTI Healthcare Fund as on 30 Apr 25
Equity Sector Allocation
Sector Value Health Care 97.95% Basic Materials 0.97% Asset Allocation
Asset Class Value Cash 1.08% Equity 98.92% Top Securities Holdings / Portfolio
Name Holding Value Quantity Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 06 | SUNPHARMA12% ₹123 Cr 672,889
↓ -27,111 Cipla Ltd (Healthcare)
Equity, Since 31 Jan 03 | 5000876% ₹62 Cr 400,000
↓ -20,000 Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 28 Feb 18 | DRREDDY5% ₹47 Cr 396,000 Ajanta Pharma Ltd (Healthcare)
Equity, Since 31 Jul 17 | 5323315% ₹47 Cr 172,829
↓ -2,056 Procter & Gamble Health Ltd (Healthcare)
Equity, Since 31 Dec 20 | PGHL4% ₹41 Cr 79,763
↑ 5,763 Apollo Hospitals Enterprise Ltd (Healthcare)
Equity, Since 30 Apr 21 | APOLLOHOSP4% ₹39 Cr 56,271 Glenmark Pharmaceuticals Ltd (Healthcare)
Equity, Since 31 Mar 24 | 5322964% ₹38 Cr 275,250 Divi's Laboratories Ltd (Healthcare)
Equity, Since 30 Sep 17 | DIVISLAB3% ₹34 Cr 56,000 Alkem Laboratories Ltd (Healthcare)
Equity, Since 31 May 21 | ALKEM3% ₹33 Cr 63,840 Fortis Healthcare Ltd (Healthcare)
Equity, Since 31 Dec 20 | 5328433% ₹32 Cr 465,000
भारत में चिकित्सा खर्च अगले पांच वर्षों में 9-12 प्रतिशत बढ़ने का अनुमान है। इसके अलावा, कोरोनावायरस के कारण घरेलू बिक्री में वृद्धि बढ़ सकती है। अधिक जोड़ने के लिए, ऐसे अस्थिर चरण में, कुछ हैंम्यूचुअल फंड्स जो अच्छा प्रदर्शन कर रहे हैं।
बाजार में जेनेरिक या नई दवाओं को तेजी से पेश करने पर ध्यान दिया जा रहा है और इससे भारतीय फार्मास्युटिकल कंपनियों को फायदा होने की उम्मीद है।
You Might Also Like